RxDoctor Payments Data

Sarah Hutchinson

Physician Assistant · Shreveport, LANPI 1770866139

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 646 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by GSK at 24.5% of the total. Among physician assistant clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,234in general payments, 2019–2025

Across 646 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Boehringer Ingelheim$978
  • United Therapeutics Corporation$552
  • Sanofi$438
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$11,78996%
  • Education$4454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,234 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$203,386
Breo ElliptaFluticasone/Vilanterol31$20,031
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$14,503
Combivent RespimatIpratropium/Albuterol Sulfate13$10,938
Spiriva RespimatTiotropium Bromide15$10,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,991
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$9,316
Wixela InhubFluticasone Propion/Salmeterol35$3,865
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,142
Roflumilast17$1,729
Albuterol Sulfate HfaAlbuterol Sulfate39$688
Ventolin HfaAlbuterol Sulfate12$656
Azithromycin46$399
Doxycycline Hyclate21$180
Methylprednisolone30$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$2,997$232,733262 claims
Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat$978$36,25847 claims
AstraZenecaBreztri Aerosphere$2,315$9,99116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →